Medtronic PLC (Germany) Insiders
| 2M6 Stock | EUR 81.88 0.73 0.88% |
Medtronic PLC employs about 22 people. The company is managed by 25 executives with a total tenure of roughly 213 years, averaging almost 8.0 years of service per executive, having 0.88 employees per reported executive. Breaking down Medtronic PLC's management performance can provide insight into the firm performance.
| Omar Ishrak Chairman Chairman of the Board, Chief Executive Officer |
| Bradley Lerman President Senior Vice President General Counsel, Corporate secretary |
Medtronic |
Medtronic PLC Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Medtronic PLC Price Series Summation is a cross summation of Medtronic PLC price series and its benchmark/peer.
Medtronic PLC Notable Stakeholders
A Medtronic PLC stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medtronic PLC often face trade-offs trying to please all of them. Medtronic PLC's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medtronic PLC's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Omar Ishrak | Chairman of the Board, Chief Executive Officer | Profile | |
| Bradley Lerman | Senior Vice President General Counsel, Corporate secretary | Profile | |
| Hooman Hakami | Executive Vice President and Group President of the Diabetes Group | Profile | |
| Richard Kuntz | Senior Vice President and Chief Scientific, Clinical and Regulatory Officer | Profile | |
| Robert White | Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group | Profile | |
| Sean Salmon | Executive Vice President and President, Cardiovascular Portfolio, Diabetes Operating | Profile | |
| Carol Surface | Chief Human Resource Officer, Senior Vice President | Profile | |
| Karen Parkhill | Chief Financial Officer, Executive Vice President | Profile | |
| Geoffrey Martha | Executive Vice President and President - Restorative Therapies Group | Profile | |
| Robert Hoedt | Executive Vice President and President - EMEAC | Profile | |
| Michael Coyle | Executive Vice President Group President - Cardiac and Vascular Group | Profile | |
| Scott Donnelly | Independent Director | Profile | |
| Richard Anderson | Lead Independent Director | Profile | |
| Elizabeth Nabel | Independent Director | Profile | |
| James Lenehan | Independent Director | Profile | |
| Craig Arnold | Independent Director | Profile | |
| Kendall Powell | Independent Director | Profile | |
| Denise OLeary | Independent Director | Profile | |
| Michael Leavitt | Independent Director | Profile | |
| Randall Hogan | Independent Director | Profile | |
| Brett Wall | Executive Vice President and President Restorative Therapies Group | Profile | |
| John Liddicoat | Executive Vice President and President Americas Region | Profile | |
| Kevin Lofton | Independent Director | Profile | |
| Sally Saba | Chief Inclusion and Diversity Officer | Profile | |
| Andrea Goldsmith | Independent Director | Profile |
About Medtronic PLC Management Performance
The success or failure of an entity such as Medtronic PLC often depends on how effective the management is. Medtronic PLC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medtronic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medtronic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in Medtronic PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medtronic PLC. Check Medtronic PLC's Beneish M Score to see the likelihood of Medtronic PLC's management manipulating its earnings.
Additional Tools for Medtronic Stock Analysis
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.